hrtechoutlook
Home» Employee Benefits Administration » CRUX

CRUX
Rewriting the Economics of Specialty-Medication Benefits

Chip Nash, CRUX | HR Tech Outlook | Specialty Employee Benefits Platform of the YearChip Nash, Co-founder and CEO
In early 2024, CRUX, a next-generation specialty-medication benefits platform, approached leading GLP-1 manufacturers with a new idea for employer-funded access to these medications, one that went beyond securing better pricing.

Direct-to-employer was still an emerging channel, taking shape alongside manufacturers’ move toward direct-to-consumer models. Crux, recently named Specialty Employee Benefits Platform of the Year 2026 by HR Tech Outlook, saw an opportunity to carry that direct-channel approach into employer-sponsored benefits, establishing a route between manufacturers and the organizations funding care.

GLP-1s had set events in motion that created a rare opportunity for alignment. Member demand was accelerating, employers were facing rising costs and opaque pricing and manufacturers were increasingly open to alternative distribution channels.

“GLP-1s are really where pain and lack of transparency, member demand and manufacturer willingness all converged first,” says Chip Nash, co-founder and CEO.

Crux’s idea was straightforward. Extend manufacturer pricing beyond traditional pharmacy benefit manager (PBM) pathways, directly to employers, by building the infrastructure to handle pricing, eligibility and payment automatically. Employers could choose how much they contributed per prescription, with every dollar of that contribution flowing directly to members as a reduction in their cost.

What emerged from the initial idea now operates as a specialty-medication coverage operating adjacent to an employer’s existing health plan. Crux functions as the transaction and compliance layer behind the direct-to-employer model, turning manufacturer pricing and employer contribution decisions into a benefit that can be administered across an eligible population. It passes pricing through without a spread and can integrate optional clinical support around treatment. Manufacturers set the product and price. Employers access those terms uniformly, with transparency and choice built in as the default.

“We need to be doing a lot more to help employers because they’re really the backbone, the financial engine behind the private American healthcare system,” says Nash.

Changing What Employers Pay and How They Budget

The platform’s biggest advantage is how it exposes true prescription costs and eliminates rebate float. In a traditional PBM model, a plan may pay roughly $1,200 at the point of sale and receive a portion back months later through rebates. The amount and timing vary by contract. A mid-sized employer with roughly 1,000 covered lives and a few hundred GLP-1 users can carry close to $1 million in rebate float at any moment.

“It’s almost like an interest-free loan that they’re giving to the PBM,” says Blake Watts, head of GTM and channel partnerships.

Crux removes that rebate float from the transaction. Employers set a fixed contribution per prescription, established in advance and applied when an employee places their medication order. The net employer cost of a GLP-1 under traditional models often ranges from $600 to $700 per unit. Through Crux, employers can choose a contribution amount that fits their budget. Many land in the $200 to $300 range, reducing the employer-funded amount per prescription by half or more while preserving member access.

Knowing the contribution upfront gives employers a clearer way to budget for the benefit. In addition to setting contribution levels, employers define eligibility and estimate utilization. Crux administers those contributions through HRAs while supporting eligibility and compliance requirements. Employers work from known unit economics instead of forecasting around unpredictable rebate cycles.

“It’s really an easy math equation in terms of deciding the level of contribution per transaction and then determining an estimate on utilization,” says Shelly Scallon, head of client success. “That helps employers really budget for the year.”

Crux’s structure gives employers flexibility to align contributions with workforce needs and budget constraints, without defaulting to restrictive utilization controls.

“The solution that’s been proposed to employers to help address high costs has been these utilization controls,” says Nash. “They’re essentially barriers that are designed to make it harder for people to access the medicine.”

Cost pressure is already forcing some employers to reconsider coverage. Watts points to a Business Group on Health survey indicating that 10 percent of employers covering GLP-1 medications in 2026 expected to drop that coverage in 2027. For Crux, that trend reinforces the need for another option that doesn’t mean choosing between absorbing the full cost and removing access altogether.

Making Transparency Part of the Member Experience

What employers gain in cost visibility, members gain in a clearer purchasing experience. Once an employer sets contribution and eligibility, Crux manages setup and launch communications. Members register on MyCrux, a co-branded member portal, ask their doctor or prescriber to send in the prescription and complete the purchase

“It is a very easy consumer experience,” says Scallon. Members see the manufacturer price, platform fees, employer contribution and their remaining cost, including support for FSA and HSA payments. Transparency is part of the transaction itself, not something employers reconcile months later.

Crux sits alongside an employer’s existing health plan, creating a dedicated layer where specialty-medication pricing, eligibility and contributions can be managed. Employers determine who receives the benefit, how much they contribute and when it becomes available; Crux administers those decisions across the eligible population.

Connecting Access to Better Outcomes

Medication cost is only one barrier to treatment success. Members often discontinue therapy because of side effects, titration challenges, or insufficient nutrition and lifestyle support.

“Adherence is one of the biggest predictors of great health outcomes,” says Watts.

Crux addresses this issue by enabling critical support that extends beyond medication access. Its platform allows employers to integrate prescribing services, lifestyle programs and medical nutrition therapy into the same experience, either through existing partners or clinical partners within Crux’s ecosystem.

Crux keeps these components connected while allowing employers to choose the level of clinical support their population needs. It does not require every organization to adopt one clinical model.

Building the Model Beyond GLP-1s

GLP-1s provided the first proving ground, but Crux is building for a much broader landscape.

“We’re seeing advancements in science and medicine that will continue to hit the market into the 2030s and the 2040s,” says Nash.

New therapies in neuroscience, autoimmune disease, dermatology and other categories will bring their own challenges around affordability and access. Crux is extending its direct-to-employer infrastructure into these specialty areas, carrying forward the transparent pricing, employer-controlled contributions and compliance support established with GLP-1s.

The longer-term opportunity goes beyond pharmacy. Fertility, mental and behavioral health, musculoskeletal care and other employer-funded programs all require organizations to decide what to offer, how much to fund and which solutions best fit their workforce.

Crux’s roadmap includes comparative analytics, benefit-design support and simplified procurement to help employers make decisions across a wider benefits portfolio. Rather than treating each new program as a separate purchasing and administration challenge, Crux sees its infrastructure becoming a common layer through which employers can compare options, configure benefits and manage spending around their own priorities.

“We really haven’t even scratched the surface in terms of what our ultimate vision is,” says Nash.

That broader ambition builds on a model already gaining recognition in the market. Crux was named Specialty Employee Benefits Platform of the Year 2026 by HR Tech Outlook, reflecting its approach to giving employers greater visibility into cost, more control over contributions and a clearer path to specialty-medication access.

As Crux expands into new therapies and benefit categories, that same foundation positions the platform to help employers make increasingly complex funding decisions with greater clarity and control.

Deep Dive

Making Specialty Medication Benefits Easier to Fund

Specialty medication benefits have become harder to price because the amount charged at the pharmacy can differ sharply from the employer’s eventual net cost. Rebates may arrive months later, leaving plan funds tied up while finance teams estimate what will ultimately be returned. At the same time, employers are being asked to preserve access to high-demand therapies without giving up budget control. A specialty employee benefits platform should therefore make current unit economics visible and give sponsors direct control over what they contribute. Pricing transparency matters most when it changes how an employer funds the benefit. Traditional rebate structures can force a plan to pay the full transaction price, then wait for part of that money to come back. That delay creates cash-flow exposure and makes annual forecasting less precise. A better structure lets the employer see the underlying medication price when the transaction occurs and apply a defined contribution at that point. The finance question becomes easier to model because the sponsor is deciding what it will spend rather than forecasting both gross spend and uncertain rebate timing. Contribution design is equally important. Employers do not all want to subsidize specialty medications at the same level, and a platform should not lock every plan into the same economics. Contribution amounts need to be configurable by the employer and supported by eligibility rules that can be applied consistently across the covered population. That allows a sponsor to shape access around its workforce and benefit budget while keeping the contribution mechanism administratively clear. Member access adds another layer. Price visibility loses much of its usefulness if employees still face a confusing transaction after a prescription is written. A strong platform should make the employer contribution and remaining member cost easy to see before payment, with applicable fees disclosed alongside them. Payment flexibility also matters because employees may want to use health accounts or other permitted methods rather than rely on a single checkout path. The underlying process should remain simple enough that benefit design decisions do not create avoidable friction at the point of use. Administrative scope should also be examined closely. Employers need clear enrollment and eligibility handling without rebuilding pharmacy administration inside HR. Communication templates and eligibility file support can reduce setup work, while configurable timing gives employers more control over rollout. Integrations with prescribing or clinical partners can support employers that want additional care services around the medication benefit. The key is modularity. Buyers should be able to add support where it serves the plan rather than accept a bundled structure that dictates the full member journey. Crux gives employers direct access to manufacturer-based specialty medication pricing through a platform that lets them set contribution levels and apply those contributions across eligible employees. Crux also supports setup through eligibility loading and launch materials while keeping medication pricing and employer contributions visible to members during checkout. The model removes rebate timing from the transaction, which can make current spending easier to understand and budget. MyCrux also allows multiple payment methods and can connect employers with clinical or lifestyle support partners when those services are wanted. For buyers focused on price visibility and configurable employer funding, Crux warrants serious consideration as a specialty benefits platform. ...Read more
Specialty Employee Benefits Platform of the Year 2026

Company
CRUX

Management
Chip Nash, Co-founder and CEO

Description
Crux is a direct-to-employer specialty benefits platform connecting employers with pharmaceutical manufacturers and benefit partners. Its model brings greater transparency, flexibility and employer choice to specialty medications while supporting benefit administration, compliance and access.